专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080188435A1 Methods of dignosing or treating depression on basis of increased cerebrospinal fluid levels of neurotrodhin 3 审中-公开
标题翻译：基于神经毒素增加的脑脊液水平来抑制或治疗抑郁症的方法3
公开(公告)号：US20080188435A1
公开(公告)日：2008-08-07
申请号：US12003851
申请日：2008-01-02
申请人： Roger Nitsch , Christoph Hock , Uwe Otten
发明人： Roger Nitsch , Christoph Hock , Uwe Otten
IPC分类号： A61K31/70 , C12Q1/02 , C12Q1/68 , A61P25/00 , G01N33/567
CPC分类号： G01N33/6896 , G01N2333/4709 , G01N2333/475 , G01N2800/304
摘要： The invention relates to a method for diagnosing or prognosing depression, in particular major depression, in a subject, or determining whether a subject is at increased risk of developing depression, in particular major depression, comprising: determining a level, or an activity, or both said level and said activity, of neurotrophin 3 and/or of a transcription product of a gene coding for neurotrophin 3 in a sample from said subject; and comparing said level, or said activity, or both said level and said activity, to a reference value representing a known disease or health status, thereby diagnosing or prognosing depression in said subject, or determining whether said subject is at increased risk of developing said depression.
摘要翻译：本发明涉及用于诊断或预测受试者中抑郁症，特别是抑郁症的方法，或确定受试者是否处于发展中的抑郁症，特别是重度抑郁症的风险增加的方法，其包括：确定水平或活动，或在所述受试者的样品中表达神经营养因子3和/或编码神经营养因子3的基因的转录产物的水平和所述活性; 以及将所述水平或所述活动或所述水平和所述活动两者比较为代表已知疾病或健康状况的参考值，从而诊断或预测所述受试者的抑郁症，或者确定所述受试者是否处于发展所述受试者的风险增加萧条。

2. 发明申请

US20050130233A1 Methods of diagnosing or treating Alzheimer's disease on basis of increased cerebrospinal fluid levels of nerve growth factor 审中-公开
标题翻译：基于神经生长因子的脑脊液水平升高来诊断或治疗阿尔茨海默病的方法
公开(公告)号：US20050130233A1
公开(公告)日：2005-06-16
申请号：US10987298
申请日：2004-11-15
申请人： Roger Nitsch , Christoph Hock , Uwe Otten
发明人： Roger Nitsch , Christoph Hock , Uwe Otten
IPC分类号： A61K38/18 , G01N33/53 , G01N33/68 , G01N33/567
CPC分类号： A61K38/185 , G01N33/6896 , G01N2333/4709 , G01N2333/48 , G01N2800/2821
摘要： A method for diagnosing or prognosing Alzheimer's disease in a subject, or determining whether a subject is at increased risk of developing Alzheimer's disease, involves determining a level, or an activity, or both the level and the activity, of nerve growth factor in a sample taken from cerebrospinal fluid of the subject, and comparing the level, or the activity, or both the level and the activity, to a reference value representing a known disease or health status, wherein a varied level, or activity, or both the level and the activity, of nerve growth factor in the cerebrospinal fluid from the subject relative to the reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of the Alzheimer's disease in the subject.
摘要翻译：用于诊断或预测受试者中的阿尔茨海默病的方法，或确定受试者是否处于发展中的阿尔茨海默氏病的风险增加涉及确定样品中神经生长因子的水平或活性或水平和活性两者取自受试者的脑脊液，并将水平或活动，或水平和活动两者比较为代表已知疾病或健康状况的参考值，其中变化的水平或活动，或水平和来自受试者的脑脊液中的神经生长因子相对于代表已知健康状态的参考值的活性表示受试者中阿尔茨海默病的诊断或预后或增加的风险。

3. 发明授权

US08906367B2 Method of providing disease-specific binding molecules and targets 有权
标题翻译：提供疾病特异性结合分子和靶标的方法
公开(公告)号：US08906367B2
公开(公告)日：2014-12-09
申请号：US12522031
申请日：2008-01-07
申请人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
IPC分类号： A61K39/395 , C07K16/00 , C12N15/00 , C12P21/00 , C07K16/18 , A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/77
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译：提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在的正常生理环境。此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。

4. 发明申请

US20140044644A1 ANKYRIN G AND MODULATORS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS 审中-公开
标题翻译： ANKYRIN G及其治疗神经损伤性疾病的调节剂
公开(公告)号：US20140044644A1
公开(公告)日：2014-02-13
申请号：US14000454
申请日：2012-02-21
申请人： Antonella Santuccione Chadha , Mario Merlini , Roger Nitsch , Jan Grimm , Christoph Hock
发明人： Antonella Santuccione Chadha , Mario Merlini , Roger Nitsch , Jan Grimm , Christoph Hock
IPC分类号： A61K39/395 , G01N33/68 , A61K31/7088 , A61K49/00 , A61K38/17 , A61K31/713
CPC分类号： A61K39/3955 , A01K2267/0312 , A61K31/7088 , A61K31/713 , A61K38/17 , A61K38/1709 , A61K39/0007 , A61K49/0004 , A61K2039/55566 , C07K16/18 , C12N2770/36143 , G01N33/6896 , G01N2333/4709 , G01N2500/00 , G01N2800/2821
摘要： The present invention generally relates to the technical field of medicine, in particular to the field of neurodegenerative, neurological and protein misfolding disorders such as amyloidosis. By establishing a role of ankG in APP processing the method of the present invention provides a new insight into the role of ankG in AD pathology and provides ankG as a target, drug, diagnostic agent and particularly as a vaccine in the treatment and diagnosis of the pathogenesis of Alzheimer's disease (AD).
摘要翻译：本发明一般涉及医学技术领域，特别涉及神经变性，神经和蛋白质错误折叠疾病如淀粉样变性的领域。通过在APP处理中建立ankG的作用，本发明的方法提供了对adkG在AD病理学中的作用的新见解，并提供ankG作为靶标，药物，诊断剂，特别是作为疫苗治疗和诊断阿尔茨海默氏病（AD）的发病机制。

5. 发明申请

US20120087861A1 Human Anti-Tau Antibodies 有权
标题翻译：人抗Tau抗体
公开(公告)号：US20120087861A1
公开(公告)日：2012-04-12
申请号：US13271118
申请日：2011-10-11
申请人： Roger Nitsch , Feng Chen , Jan Grimm , Jean-Luc Baeriswyl , Christoph Hock
发明人： Roger Nitsch , Feng Chen , Jan Grimm , Jean-Luc Baeriswyl , Christoph Hock
IPC分类号： A61K51/10 , C12N15/13 , C12N15/63 , C12N1/21 , C12N1/19 , C12N5/10 , C12P21/08 , C12N9/96 , A61K39/395 , C40B30/04 , G01N33/566 , A61K49/16 , A61K49/00 , A61P25/28 , A61P25/16 , A61P25/00 , C07K16/18
CPC分类号： C07K16/18 , A61K39/3955 , A61K2039/505 , C07K14/47 , C07K14/4711 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/90 , C07K2317/92 , G01N33/6896 , G01N2333/47 , G01N2800/56
摘要： Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
摘要翻译：提供新的人tau特异性抗体以及其片段，衍生物和变体以及与之相关的方法。还公开了与特异于tau的抗体相关的测定，试剂盒和固体支持物。抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于tau靶向免疫治疗和诊断的药物和诊断组合物中。

6. 发明授权

US09283271B2 Human anti-SOD1 antibodies 有权
标题翻译：人抗SOD1抗体
公开(公告)号：US09283271B2
公开(公告)日：2016-03-15
申请号：US13992840
申请日：2011-12-19
申请人： Fabio Montrasio , Maria Grazia Barenco Montrasio , Jan Grimm , Roger Nitsch , Christoph Hock , Marcel Maier
发明人： Fabio Montrasio , Maria Grazia Barenco Montrasio , Jan Grimm , Roger Nitsch , Christoph Hock , Marcel Maier
IPC分类号： A61K39/395 , A61K39/00 , C07K14/435 , C07K16/40 , C12N9/02 , A61K45/06 , A61K47/48 , A61K49/08 , A61K51/10 , G01N33/573
CPC分类号： C07K16/40 , A61K39/0005 , A61K39/3955 , A61K45/06 , A61K47/6871 , A61K49/085 , A61K51/10 , A61K2039/505 , C07K14/435 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C12N9/0089 , G01N33/573 , G01N33/577 , G01N33/6893 , G01N2333/90283 , G01N2800/28 , G01N2800/285
摘要： Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
摘要翻译：提供新型人铜 - 锌超氧化物歧化酶，也称为超氧化物歧化酶1或SOD1，特异性抗体以及其片段，衍生物和变体以及与之相关的方法。还公开了与SOD1特异性抗体相关的测定，试剂盒和固体支持物。抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于SOD1靶向免疫治疗和诊断的药物和诊断组合物中。

7. 发明申请

US20140301945A1 HUMAN ANTI-SOD1 ANTIBODIES 有权
标题翻译：人类抗-SOD1抗体
公开(公告)号：US20140301945A1
公开(公告)日：2014-10-09
申请号：US13992840
申请日：2011-12-19
申请人： Fabio Montrasio , Maria Grazia Barenco Montrasio , Jan Grimm , Roger Nitsch , Christoph Hock , Tobias Welt , Jordan McAfoose , Marcel Maier
发明人： Fabio Montrasio , Maria Grazia Barenco Montrasio , Jan Grimm , Roger Nitsch , Christoph Hock , Tobias Welt , Jordan McAfoose , Marcel Maier
IPC分类号： A61K39/395 , A61K49/08 , G01N33/573 , A61K45/06 , A61K47/48 , C12N9/02 , A61K51/10 , C07K16/40
CPC分类号： C07K16/40 , A61K39/0005 , A61K39/3955 , A61K45/06 , A61K47/6871 , A61K49/085 , A61K51/10 , A61K2039/505 , C07K14/435 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C12N9/0089 , G01N33/573 , G01N33/577 , G01N33/6893 , G01N2333/90283 , G01N2800/28 , G01N2800/285
摘要： Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
摘要翻译：提供新型人铜 - 锌超氧化物歧化酶，也称为超氧化物歧化酶1或SOD1，特异性抗体以及其片段，衍生物和变体以及与之相关的方法。还公开了与SOD1特异性抗体相关的测定，试剂盒和固体支持物。抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于SOD1靶向免疫治疗和诊断的药物和诊断组合物中。

8. 发明申请

US20060240485A1 Method of monitoring immunotherapy 审中-公开
标题翻译：监测免疫治疗的方法
公开(公告)号：US20060240485A1
公开(公告)日：2006-10-26
申请号：US10554314
申请日：2003-10-15
申请人： Christoph Hock , Uwe Konietzko , Roger Nitsch
发明人： Christoph Hock , Uwe Konietzko , Roger Nitsch
IPC分类号： G01N33/567 , G01N33/53
CPC分类号： G01N33/6896 , G01N2333/4709 , G01N2800/2821
摘要： The present invention relates to a method of monitoring an immunotherapy against amyloidosis and other diseases characterized by the deposition of abnormal protein aggregates. More specifically, it relates to a method of evaluating an immunotherapy against Alzheimer's disease, based on a novel assay that is characterized by scoring immunoreactivity levels of patient sera in amyloid plaque containing samples. The assay possesses highly predictive properties in relation to the clinical outcome of such an immunotherapy, in contrast to previously used, conventional ELISA assays. Therefore, the novel assay is useful for the evaluation of the efficacy of an immunotherapy in a patient suffering from amyloidosis, particularly Alzheimer's disease.
摘要翻译：本发明涉及一种监测免疫治疗抗淀粉样变性和其它特征在于沉积异常蛋白质聚集体的疾病的方法。更具体地，本发明涉及一种基于新型测定方法，该方法的特征在于评估含有淀粉样蛋白斑块的样品中患者血清的免疫反应性水平。与以前使用的常规ELISA测定法相比，该测定法与这种免疫治疗的临床结果相关具有高度预测性质。因此，该新型测定法可用于评价患有淀粉样变性疾病，特别是阿尔茨海默氏病的患者中的免疫治疗的功效。

9. 发明授权

US09580493B2 Anti-α synuclein binding molecules 有权
标题翻译：抗α突触核蛋白结合分子
公开(公告)号：US09580493B2
公开(公告)日：2017-02-28
申请号：US14128497
申请日：2012-06-22
申请人： Andreas Weihofen , Jan Grimm , Christoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
发明人： Andreas Weihofen , Jan Grimm , Christoph Hock , Roger Nitsch , Lihe Su , Paul Weinreb
IPC分类号： A61K39/395 , C12P21/08 , C07K16/18 , G01N33/68
CPC分类号： C07K16/18 , A61K47/6849 , C07K2317/34 , C07K2317/565 , G01N33/6896 , G01N2333/47 , G01N2800/28 , G01N2800/2828 , G01N2800/2835
摘要： Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
摘要翻译：提供抗人α-突触核蛋白特异性结合分子，例如抗体或抗原结合片段，其变体或衍生物，作为与其相关的方法。还提供了结合人α-突触核蛋白上的特异性N末端和C-末端表位的抗人α-突触核蛋白结合分子。本文所述的结合分子可分别用于α-突触核蛋白靶向免疫治疗和诊断的药物和诊断组合物中。

10. 发明申请

US20100202968A1 Method of Providing Disease-Specific Binding Molecules and Targets 有权
标题翻译：提供疾病特异性结合分子和靶标的方法
公开(公告)号：US20100202968A1
公开(公告)日：2010-08-12
申请号：US12522031
申请日：2008-01-07
申请人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
IPC分类号： A61K49/00 , G01N33/50 , C07K16/00 , C07H21/00 , C12N15/74 , C12N5/10 , C12P21/02 , A61K31/7088 , A61K35/12 , A61K39/395 , A61K39/00 , A61P25/28
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/77
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译：提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在的正常生理环境。此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式